Global Anticoagulation Therapy Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 29.97 Billion |
 Market Size (Forecast Year) |
USD 57.10 Billion |
 CAGR |
% |
| Major Markets Players |
|
>全球抗凝治疗市场，按治疗（深静脉血栓形成 (DVT)、肺栓塞 (PE)、动脉血栓栓塞症 (AT)、中风等）、治疗类别（新型口服抗凝剂 (NOAC)、肝素、维生素 K 拮抗剂等）、药物类型（比伐卢定、达比加群、依多沙班、贝曲沙班、利伐沙班、阿哌沙班、依诺肝素、达肝素等）、给药途径（口服和肠外）、治疗领域（心血管、呼吸、肿瘤、肾脏病、中枢神经系统等）、程序（术前程序、术后程序、肾透析和心脏瓣膜置换）、类型（仿制药和品牌药）、最终用户（医院、诊所、家庭护理、门诊手术中心和其他）、分销渠道（医院药房、零售药房和网上药房）——行业趋势和预测至 2031 年。
抗凝治疗市场分析及规模
在最新方法和技术的推动下，抗凝治疗市场正在经历重大进步。这种增长是由对更有效的治疗方法的使用和需求增加所推动的，例如新型口服抗凝剂 (NOAC) 和精准医疗方法。这些创新旨在通过提供更安全、更有针对性的治疗方案来改善患者的治疗效果，标志着血栓性疾病管理进入了变革阶段。
2023 年全球抗凝治疗市场规模价值 299.7 亿美元，预计到 2031 年将达到 571 亿美元，预测期内（2024 年至 2031 年）的复合年增长率为 8.39%。这表明市场价值。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022 (可定制为 2016-2021) |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, and Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, and Others), Drug Type (Bivalirudin, Dabigatran, Edoxaban, Betrixaban, Rivaroxaban, Apixaban, Enoxaparin, Dalteparin, and Others), Route of Administration (Oral and Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, and Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, and Heart Valve Replacement), Type (Generics and Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Market Players Covered |
Hikma Pharmaceuticals PLC (Jordan), Mylan N.V. (Netherlands), Teva Pharmaceutical Industries Ltd. (Israel, Novartis AG (Switzerland), Eisai Co., Ltd. (Japan), Pfizer Inc. (U.S.), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Aspen Holdings (South Africa), Shanghai Fosun Pharmaceutical(Group)Co., Ltd. (China), Cipla Inc. (India), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Eagle Pharmaceuticals, Inc. (U.S.), Endo International plc (Ireland), Mitsubishi Tanabe Pharma Corporation (Japan), Portola Pharmaceuticals, Inc. (U.S.), and Taro Pharmaceutical Industries Ltd. (Israel) |
|
Market Opportunities |
|
Market Definition
Anticoagulation therapy involves the use of medications to prevent blood clot formation in patients at risk of thrombosis. These drugs, such as warfarin or heparin, work by interfering with the blood's ability to clot, reducing the likelihood of dangerous clotting within blood vessels. This therapy is crucial in managing conditions such as deep vein thrombosis, pulmonary embolism, and preventing stroke in individuals with atrial fibrillation.
Anticoagulation Therapy Market Dynamics
Drivers
- Increasing Prevalence of Cardiovascular Diseases
The rising global prevalence of cardiovascular diseases, including heart attacks and strokes, has fueled the demand for anticoagulation therapy. These conditions often require preventive measures against blood clotting to manage and reduce risks. For instance, atrial fibrillation, a common heart rhythm disorder, significantly increases the risk of stroke and necessitates ongoing anticoagulant treatment to prevent clot formation and potential stroke events, thereby driving growth in the anticoagulation therapy market.
- Growing Aging Population
The growing aging population is a pivotal driver for the anticoagulation therapy market. As people age, conditions such as atrial fibrillation and deep vein thrombosis become more prevalent. For instance, individuals over 65 are at higher risk of developing atrial fibrillation, necessitating anticoagulation therapy to prevent strokes. This demographic shift increases the demand for anticoagulants, contributing significantly to the expansion of the market for these therapies.
Opportunities
- Advancements in Anticoagulant Drugs
Advancements in anticoagulant drugs are driving the market by continually introducing more effective treatments. For instance, the development of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban offers patients alternatives to traditional therapies such as warfarin. These medications provide more predictable anticoagulation effects, require less frequent monitoring, and have lower risks of drug interactions, thereby improving patient outcomes and expanding the overall anticoagulation therapy market.
- Increasing Surgical Procedures
Increasing surgical procedures, particularly joint replacements and major orthopedic surgeries, drive the anticoagulation therapy market. These procedures often require prophylactic anticoagulation to prevent complications such as deep vein thrombosis (DVT) and pulmonary embolism (PE). For instance, after hip replacement surgery, patients are at high risk of DVT, necessitating the use of anticoagulants such as heparin or newer agents such as direct oral anticoagulants (DOACs). This demand fuels growth in the market for anticoagulation therapies.
Restraints/Challenges
- Side Effects and Bleeding Risks
Anticoagulants pose significant risks of bleeding, especially in elderly patients or those with specific medical conditions, which hinders their market acceptance. The potential for severe bleeding events remains a critical concern, deterring broader adoption despite their therapeutic benefits in preventing thrombotic events.
- High Cost of Therapy
The high cost of newer anticoagulants poses a significant barrier to market accessibility, particularly for patients lacking comprehensive insurance coverage or residing in lower-income regions. This financial constraint limits widespread adoption and availability, exacerbating disparities in access to essential anticoagulation therapies across global healthcare systems.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In July 2023, The Assure PT Care PT/INR Monitoring System, a collaboration between ARKRAY USA, Inc. and CoaguSense, Inc., will be available in long-term care institutions. This point-of-care test utilizes a proprietary micromechanical device for blood clotting time detection, comparable to WHO's tilt-tube method. Its wireless, portable design aims to enhance PT/INR testing productivity with instant results for timely patient care decisions
- In May 2023, Pfizer reported successful phase 3 results for marstacimab in treating hemophilia A and B, demonstrating efficacy without clotting issues. Annualized bleeding rates were significantly lower compared to current intravenous regimens, indicating clinical relevance. If approved, marstacimab would offer a flat dosage and be the first weekly subcutaneous treatment for hemophilia B
- In February 2022, Bayer's oral Factor Xia inhibitor Asundexian received fast-track designation from the FDA. In phase 2 trials, it promises safety advantages over existing anticoagulants. This potential therapy addresses a critical need for improved anticoagulation options
- In February 2022, Techdow USA Inc. launched its Heparin Sodium Injection, USP in the U.S. market. As a vertically integrated generic injectables company, this product aims to meet demand for high-quality injectable heparin sodium, contributing to healthcare accessibility and patient care in the United States
Anticoagulation Therapy Market Scope
The market is segmented on the basis of treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Arterial Thromboembolism (AT)
- Stroke
- Others
Therapeutic Class
- Novel Oral Anticoagulants (NOAC)
- Heparin
- Vitamin K Antagonists
- Others
Drug Type
- Bivalirudin
- Dabigatran
- Edoxaban
- Betrixaban
- Rivaroxaban
- Apixaban
- Enoxaparin
- Dalteparin
- Others
Route of Administration
- Oral
- Parenteral
Therapeutic Area
- Cardiovascular
- Respiratory
- Oncology
- Nephrology
- CNS
- Others
Procedure
- Pre-Surgical Procedures
- Post-Surgical Procedures
- Kidney Dialysis
- Heart Valve Replacement
Type
- Generics
- Branded
End User
- Hospitals
- Clinics
- Homecare
- Ambulatory Surgical Centres
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Anticoagulation Therapy Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to expand at a significant growth rate due to the enduring administration, triple therapy anticoagulation, and increasing demand for anticoagulation drugs. The region's focus on long-term medical therapies drives the market for these treatments, reflecting sustained growth over the forecast period.
North America is expected to dominate the anticoagulation therapy market due to the proliferation of hospital-associated clinics and substantial healthcare expenditure in the region. These factors underscore its leading position in advancing anticoagulation treatments and patient care.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Anticoagulation Therapy Market Share Analysis
市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
市场上的一些主要参与者包括：
- Hikma Pharmaceuticals PLC（约旦）
- Mylan NV（荷兰）
- Teva Pharmaceutical Industries Ltd.（以色列）
- 诺华公司（瑞士）
- 卫材株式会社（日本）
- 辉瑞公司（美国）
- 赛诺菲（法国）
- F. Hoffmann-La Roche Ltd（瑞士）
- 费森尤斯卡比公司（德国）
- 阿斯彭控股 (南非)
- 上海复星医药(集团)股份有限公司 (中国)
- Cipla Inc.（印度）
- 强生服务公司（美国）
- 拜耳公司（德国）
- 勃林格殷格翰国际有限公司 (德国)
- 百时美施贵宝公司 (美国)
- 第一三共株式会社（日本）
- Eagle Pharmaceuticals, Inc.（美国）
- Endo International plc（爱尔兰）
- 田边三菱制药株式会社（日本）
- Portola Pharmaceuticals, Inc.（美国）
- Taro Pharmaceutical Industries Ltd.（以色列）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
